SRR_accession	QC_summary	SRX_accession	SRS_accession	SRP_accession	Experiment_title	GEO_series	sample_alias	study_accession	experiment_accession	experiment_title	sample_taxon_id	sample_scientific_name	experiment_library_strategy	experiment_library_source	experiment_library_selection	sample_accession	experiment_instrument_model	run_1_size	run_1_total_spots	run_1_total_bases
SRR34562517	PASS	SRX29704696	SRS25814445	SRP601346	GSM9104933: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104933	SRP601346	SRX29704696	GSM9104933: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814445	Illumina NovaSeq 6000	  2953323697	  29724528	  8917358400
SRR34562518	PASS	SRX29704695	SRS25814444	SRP601346	GSM9104932: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104932	SRP601346	SRX29704695	GSM9104932: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814444	Illumina NovaSeq 6000	  2135020924	  21687744	  6506323200
SRR34562519	PASS	SRX29704694	SRS25814443	SRP601346	GSM9104931: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104931	SRP601346	SRX29704694	GSM9104931: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814443	Illumina NovaSeq 6000	  1974617019	  19980995	  5994298500
SRR34562520	PASS	SRX29704693	SRS25814442	SRP601346	GSM9104930: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104930	SRP601346	SRX29704693	GSM9104930: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814442	Illumina NovaSeq 6000	  2208905109	  22224137	  6667241100
SRR34562521	PASS	SRX29704692	SRS25814441	SRP601346	GSM9104929: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104929	SRP601346	SRX29704692	GSM9104929: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814441	Illumina NovaSeq 6000	  2403133993	  24247901	  7274370300
SRR34562522	PASS	SRX29704691	SRS25814440	SRP601346	GSM9104928: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104928	SRP601346	SRX29704691	GSM9104928: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814440	Illumina NovaSeq 6000	  2129352749	  20925246	  6277573800
SRR34562523	PASS	SRX29704690	SRS25814439	SRP601346	GSM9104927: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104927	SRP601346	SRX29704690	GSM9104927: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814439	Illumina NovaSeq 6000	  2024658198	  20005136	  6001540800
SRR34562524	PASS	SRX29704689	SRS25814438	SRP601346	GSM9104926: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104926	SRP601346	SRX29704689	GSM9104926: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814438	Illumina NovaSeq 6000	  2234940935	  22307038	  6692111400
SRR34562525	PASS	SRX29704688	SRS25814436	SRP601346	GSM9104925: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104925	SRP601346	SRX29704688	GSM9104925: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814436	Illumina NovaSeq 6000	  2084604193	  20649038	  6194711400
SRR34562526	PASS	SRX29704687	SRS25814437	SRP601346	GSM9104924: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104924	SRP601346	SRX29704687	GSM9104924: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814437	Illumina NovaSeq 6000	  2210830873	  21928239	  6578471700
SRR34562527	PASS	SRX29704686	SRS25814434	SRP601346	GSM9104923: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104923	SRP601346	SRX29704686	GSM9104923: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814434	Illumina NovaSeq 6000	  2470222210	  24265839	  7279751700
SRR34562528	PASS	SRX29704685	SRS25814435	SRP601346	GSM9104922: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104922	SRP601346	SRX29704685	GSM9104922: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814435	Illumina NovaSeq 6000	  2007218074	  19873712	  5962113600
SRR34562529	PASS	SRX29704684	SRS25814433	SRP601346	GSM9104921: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104921	SRP601346	SRX29704684	GSM9104921: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814433	Illumina NovaSeq 6000	  2256949092	  22255257	  6676577100
SRR34562530	PASS	SRX29704683	SRS25814432	SRP601346	GSM9104920: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104920	SRP601346	SRX29704683	GSM9104920: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814432	Illumina NovaSeq 6000	  2294017252	  22711834	  6813550200
SRR34562531	PASS	SRX29704682	SRS25814431	SRP601346	GSM9104919: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104919	SRP601346	SRX29704682	GSM9104919: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814431	Illumina NovaSeq 6000	  2915593746	  30680752	  9204225600
SRR34562532	PASS	SRX29704681	SRS25814430	SRP601346	GSM9104918: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104918	SRP601346	SRX29704681	GSM9104918: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814430	Illumina NovaSeq 6000	  2341268383	  23316922	  6995076600
SRR34562533	PASS	SRX29704680	SRS25814429	SRP601346	GSM9104917: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104917	SRP601346	SRX29704680	GSM9104917: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814429	Illumina NovaSeq 6000	  2173248311	  21717199	  6515159700
SRR34562534	PASS	SRX29704679	SRS25814428	SRP601346	GSM9104916: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104916	SRP601346	SRX29704679	GSM9104916: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814428	Illumina NovaSeq 6000	  1968694158	  19413789	  5824136700
SRR34562535	PASS	SRX29704678	SRS25814427	SRP601346	GSM9104915: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104915	SRP601346	SRX29704678	GSM9104915: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814427	Illumina NovaSeq 6000	  2290543856	  23030631	  6909189300
SRR34562536	PASS	SRX29704677	SRS25814426	SRP601346	GSM9104914: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 5; Mus musculus; RNA-Seq	GSE302489	GSM9104914	SRP601346	SRX29704677	GSM9104914: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 5; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814426	Illumina NovaSeq 6000	  2068970013	  20386527	  6115958100
SRR34562537	PASS	SRX29704676	SRS25814425	SRP601346	GSM9104913: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104913	SRP601346	SRX29704676	GSM9104913: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814425	Illumina NovaSeq 6000	  2059313642	  20192259	  6057677700
SRR34562538	PASS	SRX29704675	SRS25814424	SRP601346	GSM9104912: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104912	SRP601346	SRX29704675	GSM9104912: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814424	Illumina NovaSeq 6000	  1800819035	  17623319	  5286995700
SRR34562539	PASS	SRX29704674	SRS25814422	SRP601346	GSM9104911: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104911	SRP601346	SRX29704674	GSM9104911: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814422	Illumina NovaSeq 6000	  2018670772	  20208527	  6062558100
SRR34562540	PASS	SRX29704673	SRS25814423	SRP601346	GSM9104910: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104910	SRP601346	SRX29704673	GSM9104910: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814423	Illumina NovaSeq 6000	  2264004890	  22527985	  6758395500
SRR34562541	PASS	SRX29704671	SRS25814420	SRP601346	GSM9104908: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104908	SRP601346	SRX29704671	GSM9104908: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814420	Illumina NovaSeq 6000	  2278935146	  22588063	  6776418900
SRR34562542	PASS	SRX29704670	SRS25814419	SRP601346	GSM9104907: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104907	SRP601346	SRX29704670	GSM9104907: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814419	Illumina NovaSeq 6000	  2125656363	  21143081	  6342924300
SRR34562543	PASS	SRX29704669	SRS25814418	SRP601346	GSM9104906: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104906	SRP601346	SRX29704669	GSM9104906: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814418	Illumina NovaSeq 6000	  2070188684	  20710366	  6213109800
SRR34562545	PASS	SRX29704668	SRS25814417	SRP601346	GSM9104905: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104905	SRP601346	SRX29704668	GSM9104905: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814417	Illumina NovaSeq 6000	  2352114533	  23761814	  7128544200
SRR34562546	PASS	SRX29704667	SRS25814415	SRP601346	GSM9104904: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104904	SRP601346	SRX29704667	GSM9104904: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814415	Illumina NovaSeq 6000	  1933495294	  19475239	  5842571700
SRR34562547	PASS	SRX29704666	SRS25814416	SRP601346	GSM9104903: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104903	SRP601346	SRX29704666	GSM9104903: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814416	Illumina NovaSeq 6000	  2200988148	  22026408	  6607922400
SRR34562548	PASS	SRX29704665	SRS25814414	SRP601346	GSM9104902: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104902	SRP601346	SRX29704665	GSM9104902: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814414	Illumina NovaSeq 6000	  2169590524	  22086851	  6626055300
SRR34562549	PASS	SRX29704663	SRS25814412	SRP601346	GSM9104900: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104900	SRP601346	SRX29704663	GSM9104900: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814412	Illumina NovaSeq 6000	  2091562578	  20979512	  6293853600
SRR34562550	PASS	SRX29704662	SRS25814411	SRP601346	GSM9104899: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104899	SRP601346	SRX29704662	GSM9104899: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814411	Illumina NovaSeq 6000	  2231162500	  22416737	  6725021100
SRR34562551	PASS	SRX29704661	SRS25814410	SRP601346	GSM9104898: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104898	SRP601346	SRX29704661	GSM9104898: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814410	Illumina NovaSeq 6000	  2210815556	  22262605	  6678781500
SRR34562552	PASS	SRX29704664	SRS25814413	SRP601346	GSM9104901: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104901	SRP601346	SRX29704664	GSM9104901: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814413	Illumina NovaSeq 6000	  2289691060	  23118667	  6935600100
SRR34562553	PASS	SRX29704660	SRS25814409	SRP601346	GSM9104897: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104897	SRP601346	SRX29704660	GSM9104897: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814409	Illumina NovaSeq 6000	  2329990278	  23420802	  7026240600
SRR34562554	PASS	SRX29704659	SRS25814408	SRP601346	GSM9104896: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104896	SRP601346	SRX29704659	GSM9104896: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814408	Illumina NovaSeq 6000	  2612107891	  26126157	  7837847100
SRR34562555	PASS	SRX29704658	SRS25814407	SRP601346	GSM9104895: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104895	SRP601346	SRX29704658	GSM9104895: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814407	Illumina NovaSeq 6000	  2527618160	  24465372	  7339611600
SRR34562557	PASS	SRX29704655	SRS25814404	SRP601346	GSM9104892: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104892	SRP601346	SRX29704655	GSM9104892: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814404	Illumina NovaSeq 6000	  1877166232	  18474447	  5542334100
SRR34562558	PASS	SRX29704654	SRS25814403	SRP601346	GSM9104891: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104891	SRP601346	SRX29704654	GSM9104891: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814403	Illumina NovaSeq 6000	  2163705132	  21748930	  6524679000
SRR34562559	PASS	SRX29704653	SRS25814402	SRP601346	GSM9104890: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104890	SRP601346	SRX29704653	GSM9104890: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814402	Illumina NovaSeq 6000	  2089138625	  20789998	  6236999400
SRR34562560	PASS	SRX29704656	SRS25814405	SRP601346	GSM9104893: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104893	SRP601346	SRX29704656	GSM9104893: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814405	Illumina NovaSeq 6000	  2275018565	  22609716	  6782914800
SRR34562561	PASS	SRX29704652	SRS25814401	SRP601346	GSM9104889: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489	GSM9104889	SRP601346	SRX29704652	GSM9104889: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814401	Illumina NovaSeq 6000	  2096240246	  21043604	  6313081200
SRR34562562	PASS	SRX29704651	SRS25814400	SRP601346	GSM9104888: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489	GSM9104888	SRP601346	SRX29704651	GSM9104888: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814400	Illumina NovaSeq 6000	  2037282085	  20691887	  6207566100
SRR34562563	PASS	SRX29704650	SRS25814399	SRP601346	GSM9104887: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489	GSM9104887	SRP601346	SRX29704650	GSM9104887: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814399	Illumina NovaSeq 6000	  1895362020	  18652570	  5595771000
SRR34562564	PASS	SRX29704649	SRS25814398	SRP601346	GSM9104886: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489	GSM9104886	SRP601346	SRX29704649	GSM9104886: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	  10090	Mus musculus	RNA-Seq	TRANSCRIPTOMIC	cDNA	SRS25814398	Illumina NovaSeq 6000	  2209760402	  21775788	  6532736400
